Liraglutide

Generic Name
Liraglutide
Brand Names
Saxenda, Victoza, Xultophy
Drug Type
Biotech
Chemical Formula
-
CAS Number
204656-20-2
Unique Ingredient Identifier
839I73S42A
Background

Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide was granted FDA approval on January 25, 2010.

Indication

Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m), or who are overweight (BMI≥27 kg/m) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years old who weigh ≥60 kg and have an initial BMI corresponding to obesity based on international cut-offs.

Victoza, a formulation of liraglutide used in diabetes, is indicated as an adjunct to diet and exercise to improve glycemic control in patients ≥10 years old with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease.

Liraglutide is also available in combination with insulin degludec as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus.

Associated Conditions
Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
Associated Therapies
Chronic Weight Management therapy

Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone

First Posted Date
2012-01-19
Last Posted Date
2017-12-18
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
363
Registration Number
NCT01512108
Locations
🇯🇵

Novo Nordisk Investigational Site, Yokohama-shi, Japan

Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes

First Posted Date
2012-01-19
Last Posted Date
2017-01-25
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
43
Registration Number
NCT01511692
Locations
🇩🇪

Novo Nordisk Investigational Site, Neuss, Germany

Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent

First Posted Date
2012-01-18
Last Posted Date
2017-01-26
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
223
Registration Number
NCT01511198
Locations
🇺🇸

Novo Nordisk Investigational Site, Charleston, West Virginia, United States

Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes

First Posted Date
2012-01-18
Last Posted Date
2017-01-25
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
145
Registration Number
NCT01511172
Locations
🇬🇧

Novo Nordisk Investigational Site, Yaxley. Peterborough, United Kingdom

Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

First Posted Date
2012-01-18
Last Posted Date
2017-01-26
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
20
Registration Number
NCT01511185
Locations
🇺🇸

Novo Nordisk Investigational Site, Ann Arbor, Michigan, United States

Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers

First Posted Date
2012-01-18
Last Posted Date
2015-03-26
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
32
Registration Number
NCT01511159

Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes

First Posted Date
2012-01-13
Last Posted Date
2017-01-24
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
196
Registration Number
NCT01509755
Locations
🇬🇧

Novo Nordisk Investigational Site, Worksop, United Kingdom

Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

First Posted Date
2012-01-13
Last Posted Date
2024-02-01
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
19
Registration Number
NCT01509742
Locations
🇩🇪

Novo Nordisk Investigational Site, Bad Lauterberg, Germany

Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

First Posted Date
2012-01-12
Last Posted Date
2023-11-02
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
35
Registration Number
NCT01508949
Locations
🇩🇰

Novo Nordisk Investigational Site, Frederiksberg C, Denmark

Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes

First Posted Date
2012-01-12
Last Posted Date
2017-01-24
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
17
Registration Number
NCT01508923
Locations
🇩🇰

Novo Nordisk Investigational Site, Århus C, Denmark

© Copyright 2024. All Rights Reserved by MedPath